Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.47 |
| ▸ | CNR2 | P34972 | 2/20 | 0.44 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | ICMT | O60725 | 1/20 | 0.41 |
| ▸ | ALB | P02768 | 1/20 | 0.41 |
| ▸ | CETP | P11597 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28357247 | 0.94 | CSNK1E (0.46) | KCNH2CNR2CSNK1ENPC1JAK2 | |
| SCHEMBL28357249 | 0.94 | CSNK1E (0.46) | KCNH2CNR2CSNK1ENPC1JAK2 | |
| SCHEMBL15044785 | 0.94 | CSNK1E (0.46) | KCNH2CNR2CSNK1ENPC1JAK2 | |
| SCHEMBL16525596 | 0.94 | CSNK1E (0.46) | KCNH2CNR2CSNK1ENPC1JAK2 | |
| SCHEMBL25141906 | 0.89 | ESR1 (0.44) | CNR2LMNA | |
| SCHEMBL1063983 | 0.85 | CYP1A2 (0.52) | KCNH2NPC1RAB9ALMNACYP1A2 | |
| SCHEMBL1063981 | 0.85 | CYP1A2 (0.52) | KCNH2NPC1RAB9ALMNACYP1A2 | |
| SCHEMBL28191366 | 0.84 | TP53 (0.42) | KCNH2CNR2CSNK1ELMNACYP1A2 | |
| SCHEMBL15044806 | 0.83 | CYP1A2 (0.41) | KCNH2CNR2NPC1JAK2RAB9A | |
| SCHEMBL28896896 | 0.82 | FAAH (0.43) | KCNH2CNR2CSNK1ENPC1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090030092-A1 | THICKENING AGENT | AJINOMOTO CO., INC. (JP) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030092-A1 | THICKENING AGENT | CUTA, NAAA, ACOT7 | KCNH2 1905/4885CNR2 565/4885CSNK1E 1360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.